Breast cancer patients can waive chemotherapy according to a 21 gene test carried out on tumors. Loyola Medicine oncologist Kathy Albain, MD, is foremost co-authors of the study and a representative of the clinical trial’s steering committee. The premiere author is Joseph Sparano, MD, of Montefiore Medical Center in Bronx, NY. The study was produced in co-existence with its Sunday June 3 demonstration at the plenary session of the American Society of Clinical Oncology 2018 meeting in Chicago.
Dr. Albain said that with this path breaking study we can circumvent chemotherapy in about 70 percent of patients who are inflicted with breast cancer. For the innumerable women and their doctors, the days of surety are here. Dr. Albain, the Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine, has carried out research with the 21-gene test and has also applied practically in her practice.
The test probes 21 genes from a patient’s breast cancer biopsy sample to ascertain how agile they are. The tumor is allocated a recurrence score from 0 to 100; the higher the score, the greater will be the chance of cancer recurring in distant organs thereby diminishing the prospect of survival. If patients with higher score undergo chemotherapy, the probability of return will be outstandingly reduced, sanctioning more patients to be cured.
Earlier the dilemma the doctors and the patients faced was what if the patient achieves a mid-range score. It was undetermined if the advantage of chemotherapy was considerable enough to warrant the appended risk and toxicity.